Participated · Series B · Jan 2025

Atalanta Therapeutics develops RNA interference (di-siRNA) therapies to enable durable, selective gene silencing throughout the brain and spinal cord. The company’s wholly owned pipeline targets Huntington’s disease, genetic epilepsies, severe chronic pain and other neurological diseases, alongside partnered programs with Genentech. Its lead candidates are ATL-201 for KCNT1-related epilepsy and ATL-101 for Huntington’s disease, both showing strong preclinical reductions in target gene expression, durability, and tolerability. Atalanta is progressing these programs toward IND submissions in 2025 and plans Phase 1 trials to reach clinical proof-of-concept. The company is headquartered in Boston and emphasizes delivering oligonucleotide therapies to previously inaccessible CNS regions. Atalanta Therapeutics is developing branched siRNA, a novel oligonucleotide architecture designed to silence gene expression in the central nervous system. The technology was licensed from the University of Massachusetts Medical School and is being applied across multiple neurodegenerative diseases. The company announced strategic collaborations with Biogen and Genentech to develop RNAi therapeutics for targets including HTT for Huntington’s disease and additional CNS targets related to Parkinson’s and Alzheimer’s disease. Under those collaborations Atalanta is eligible to receive development and milestone payments and royalties on any resulting products. Leadership and founding scientists named in the article include CEO Alicia Secor and founders Anastasia Khvorova, Craig Mello, and Neil Aronin, with senior scientific and business officers listed. Atalanta raised $110 million in a Series A financing announced alongside these collaborations.